Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blinded Phase 3 Multi-center Study of the Clinical and Microbiologic Efficacy of a Combination of Azithromycin and Hydroxychloroquine for Treatment of COVID-19 Infection

NCT05026801 is registered in ClinicalTrials.gov with Iterum Therapeutics, International Limited as lead sponsor.

NCT NCT05026801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05026801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blinded Phase 3 Multi-center Study of the Clinical and Microbiologic Efficacy of a Combination of Azithromycin and Hydroxychloroquine for Treatment of COVID-19 Infection
Lead sponsor
Iterum Therapeutics, International Limited
Phase
Phase 3
Overall status
Withdrawn
Start date
February 8, 2021
Completion date
August 26, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory tract infection viral